Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald B Postuma

Showing results (181-190 of 284) with videos related to

Pageof 29
Sort By:
Brain : a Journal of Neurology|January 6, 2025
Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorderAline Delva, Amélie Pelletier, Emma Somerville, et al.
Parkinsonism & Related Disorders|September 18, 2021
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experienceAurelie de Rus Jacquet, Sarah Bogard, Catherine P Normandeau, et al.
Neurology|August 3, 2012
Caffeine for treatment of Parkinson disease: a randomized controlled trialRonald B Postuma, Anthony E Lang, Renato P Munhoz, et al.
Neurology|April 20, 2018
Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorderShady Rahayel, Ronald B Postuma, Jacques Montplaisir, et al.
Sleep|March 12, 2019
Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorderShady Rahayel, Malo Gaubert, Ronald B Postuma, et al.
Parkinsonism & Related Disorders|February 5, 2026
Brain cholinergic imaging in isolated REM sleep behavior disorder: Distinctions and similarities with Parkinson's diseaseRebekah H Wickens, Ronald B Postuma, Olga Fliaguine, et al.
NPJ Parkinson'S Disease|August 13, 2025
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
NPJ Parkinson'S Disease|July 2, 2025
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Neuroscience Letters|November 16, 2004
Genetic association study of PINK1 coding polymorphisms in Parkinson's diseaseJustus L Groen, Toshitaka Kawarai, Anna Toulina, et al.
Molecular Neurodegeneration|February 11, 2025
From mechanisms to future therapy: a synopsis of isolated REM sleep behavior disorder as early synuclein-related diseaseAmbra Stefani, Elena Antelmi, Dario Arnaldi, et al.
Pageof 29

Showing results (181-190 of 284) with videos related to

Sort By:
Pageof 29
Brain : a Journal of Neurology|January 6, 2025
Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorderAline Delva, Amélie Pelletier, Emma Somerville, et al.
Parkinsonism & Related Disorders|September 18, 2021
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experienceAurelie de Rus Jacquet, Sarah Bogard, Catherine P Normandeau, et al.
Neurology|August 3, 2012
Caffeine for treatment of Parkinson disease: a randomized controlled trialRonald B Postuma, Anthony E Lang, Renato P Munhoz, et al.
Neurology|April 20, 2018
Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorderShady Rahayel, Ronald B Postuma, Jacques Montplaisir, et al.
Sleep|March 12, 2019
Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorderShady Rahayel, Malo Gaubert, Ronald B Postuma, et al.
Parkinsonism & Related Disorders|February 5, 2026
Brain cholinergic imaging in isolated REM sleep behavior disorder: Distinctions and similarities with Parkinson's diseaseRebekah H Wickens, Ronald B Postuma, Olga Fliaguine, et al.
NPJ Parkinson'S Disease|August 13, 2025
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
NPJ Parkinson'S Disease|July 2, 2025
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Neuroscience Letters|November 16, 2004
Genetic association study of PINK1 coding polymorphisms in Parkinson's diseaseJustus L Groen, Toshitaka Kawarai, Anna Toulina, et al.
Molecular Neurodegeneration|February 11, 2025
From mechanisms to future therapy: a synopsis of isolated REM sleep behavior disorder as early synuclein-related diseaseAmbra Stefani, Elena Antelmi, Dario Arnaldi, et al.
Pageof 29